Trelegy Ellipta

fluticasone furoate / umeclidinium / vilanterol

  • Email
  • Help

About

This is a summary of the European public assessment report (EPAR) for Trelegy Ellipta. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide detailed practical advice on how to use Trelegy Ellipta.

For practical information about using Trelegy Ellipta, patients should read the package leaflet or contact their doctor or pharmacist.

What is Trelegy Ellipta and what is it used for?

Trelegy Ellipta is a medicine used to relieve the symptoms of moderate to severe chronic obstructive pulmonary disease (COPD). COPD is a long-term disease in which the airways and air sacs inside the lungs become damaged or blocked, leading to difficulty breathing.

Trelegy Ellipta is used in adults whose disease is not controlled well enough with a combination of inhaled medicines called corticosteroids and long-acting beta-2 agonists. Corticosteroids reduce inflammation in the airways and lungs, and long-acting beta-2 agonists widen the airways.

Trelegy Ellipta is used for maintenance (regular) treatment on a daily basis. It contains the active substances fluticasone furoate, umeclidinium bromide and vilanterol.

How is Trelegy Ellipta used?

Trelegy Ellipta can only be obtained with a prescription. It is available as an inhalation powder, which the patient inhales through the mouth using a portable inhaler device; the patient should inhale the medicine once a day at around the same time each day. For further information, see the package leaflet.

How does Trelegy Ellipta work?

Trelegy Ellipta contains three active substances, which work in different ways to widen the airways and improve breathing in COPD.

Fluticasone furoate is a corticosteroid. It works in a similar way to naturally occurring corticosteroid hormones, reducing the activity of the immune system by attaching to receptors (targets) in various types of immune cells. This reduces the release of substances involved in the inflammation process, such as histamine, thereby reducing inflammation and helping to keep the airways clear and allowing the patient to breathe more easily.

Umeclidinium bromide is a muscarinic receptor antagonist. It works by blocking muscarinic receptors, which are involved in the contraction of muscles. When umeclidinium bromide is inhaled, it causes the muscles of the airways to relax.

Vilanterol is a long-acting beta-2 agonist. It works by attaching to beta-2 receptors in some types of muscle cells. When inhaled, vilanterol activates the beta-2 receptors in the airways. This causes the muscles of the airways to relax, helping to keep the airways open and allowing the patient to breathe more easily.

What benefits of Trelegy Ellipta have been shown in studies?

A main study involving 1,810 patients whose COPD was not satisfactorily controlled with a daily maintenance treatment for their COPD found Trelegy Ellipta more effective at improving patients’ breathing than an inhaled combination of budesonide, a corticosteroid, and formoterol, a long-acting beta-2 agonist.

After 24 weeks, patients taking Trelegy Ellipta had their FEV1 (the maximum volume of air they could breathe out in one second) improve by 142 ml. This compares with an average reduction of 29 ml seen in patients taking the combination of budesonide and formoterol over the same period. Patients treated with Trelegy Ellipta also reported improved health compared with those treated with the comparator treatment.

What are the risks associated with Trelegy Ellipta?

The most common side effects with Trelegy Ellipta (which may affect up to 1 in 10 people) are nasopharyngitis (inflammation of the nose and throat), headache and upper respiratory tract infection (nose and throat infection). More serious side effects include pneumonia (which may affect up to 1 in 10 people).

For the full list of all side effects and restrictions with Trelegy Ellipta, see the package leaflet.

Why is Trelegy Ellipta approved?

The European Medicines Agency decided that Trelegy Ellipta’s benefits are greater than its risks and recommended that it be approved for use in the EU.

The Agency concluded that Trelegy Ellipta improves lung function as well as the quality of life of patients with moderate to severe COPD.

Regarding the safety profile of the medicine, the most frequent side effects reported with Trelegy Ellipta were similar to those with the individual active substances of the medicine and are well known.

What measures are being taken to ensure the safe and effective use of Trelegy Ellipta?

Recommendations and precautions to be followed by healthcare professionals and patients for the safe and effective use of Trelegy Ellipta have been included in the summary of product characteristics and the package leaflet.

Other information about Trelegy Ellipta

The European Commission granted a marketing authorisation valid throughout the European Union for Trelegy Ellipta on 15 November 2017.

For more information about treatment with Trelegy Ellipta, read the package leaflet (also part of the EPAR) or contact your doctor or pharmacist.

Name Language First published Last updated
Trelegy Ellipta : EPAR - Summary for the public BG = bălgarski 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public ES = español 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public CS = čeština 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public DA = dansk 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public DE = Deutsch 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public ET = eesti keel 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public EL = elliniká 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public EN = English 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public FR = français 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public IT = italiano 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public LV = latviešu valoda 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public LT = lietuvių kalba 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public HU = magyar 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public MT = Malti 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public NL = Nederlands 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public PL = polski 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public PT = português 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public RO = română 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public SK = slovenčina 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public SL = slovenščina 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public FI = suomi 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public SV = svenska 2018-01-12  
Trelegy Ellipta : EPAR - Summary for the public HR = Hrvatski 2018-01-12  

This EPAR was last updated on 12/01/2018 .

Authorisation details

Product details

Product details for Trelegy Ellipta
NameTrelegy Ellipta
Agency product numberEMEA/H/C/004363
Active substance

fluticasone furoate, umeclidinium bromide, vilanterol trifenatate

International non-proprietary name (INN) or common name

fluticasone furoate / umeclidinium / vilanterol

Therapeutic area Pulmonary Disease, Chronic Obstructive
Anatomical therapeutic chemical (ATC) code
Additional monitoring

This medicine is under additional monitoring. This means that it is being monitored even more intensively than other medicines. For more information, see medicines under additional monitoring.

Publication details

Publication details for Trelegy Ellipta
Marketing-authorisation holder

GlaxoSmithKline Trading Services

Revision0
Date of issue of marketing authorisation valid throughout the European Union15/11/2017

Contact address:

Currabinny Carrigaline County
Cork
Ireland

Product information

Product information

15/11/2017  Trelegy Ellipta -EMEA/H/C/004363 --

Name Language First published Last updated
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - Product Information HR = Hrvatski 2018-01-12  

Contents

  • Annex I - Summary of product characteristics
  • Annex IIA - Manufacturing-authorisation holder responsible for batch release
  • Annex IIB - Conditions of the marketing authorisation
  • Annex IIIA - Labelling
  • Annex IIIB - Package leaflet

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.


Name Language First published Last updated
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  
Trelegy Ellipta : EPAR - All Authorised presentations HR = Hrvatski 2018-01-12  

Pharmacotherapeutic group

Therapeutic indication

Trelegy Ellipta is indicated as a maintenance treatment in adult patients with moderate to severe chronic obstructive pulmonary disease (COPD) who are not adequately treated by a combination of an inhaled corticosteroid and a long-acting β2-agonist.

Assessment History

Changes since initial authorisation of medicine

Name Language First published Last updated

Initial marketing-authorisation documents

Name Language First published Last updated
Trelegy Ellipta : EPAR - Public assessment report HR = Hrvatski 2018-01-12  
CHMP summary of positive opinion for Trelegy Ellipta HR = Hrvatski 2017-09-15